Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 32 recruiting now early-phase tilt

Long COVID: early-phase trial registry

32 of 51 indexed Long COVID trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #274 of 28,707 conditions by registered trial count.

51 US clinical trials · 32 currently recruiting · #274 of 28,707 conditions by registered trial count

Long COVID: 51 US clinical trials tracked, 32 recruiting.

Long COVID is the subject of 51 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 5 of these trials.

Enrollment posture brief

Registry condition long-covid

OPEN 32 | RECR 63% | LATE 2 | EARLY 21 | RANK #274 | SPON 5

Nearest open-share peer: Caregiver Burden (63% recruiting · 43 trials)

Long COVID (this)63%Peripheral Artery Disease54.9%Idiopathic Pulmonary Fibrosi42.3%Acute Pain25.5%Congestive Heart Failure15.4%
Open-enrollment share among volume-matched conditions near Long COVID

Long COVID lists 32 open slots (63% of 51 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Long COVID on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Long COVID is recruiting above its size-band peers.

    32 of 51 indexed trials (62.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Long COVID trials is spread across many organizations.

    Duke University accounts for 5 of 51 trials (9.8%). 35 distinct sponsors appear on at least one study for this condition label.

  3. Typical Long COVID enrolment sits around 90 participants.

    Median target enrolment is 90 among the 51 trials that report a genuine target (sentinel values excluded). 27 of those (52.9%) plan for fewer than 100 participants.

  4. Long COVID research is mostly interventional.

    47 interventional and 4 observational studies make up this index (92.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 218Phase 32

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 18
Phase 3 2

Named interventions

Most-linked intervention names on Long COVID records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Placebo Other
4 trials
Solriamfetol Placebo Drug
2 trials
Modafinil Placebo Drug
2 trials
Solriamfetol Drug
2 trials
Modafinil Drug
2 trials
Melatonin Drug
2 trials
Usual Care Behavioral
2 trials

US sites by state

Facility locations filed on Long COVID trials. A trial with sites in several states counts in each.

California 16 trials
New York 7 trials
Massachusetts 6 trials
Illinois 6 trials
Tennessee 5 trials
North Carolina 5 trials
Georgia 4 trials
Utah 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Long COVID page

51 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Long COVID condition card totals 51 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.